VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Search Videos by Topic or Participant
Browse by Series:

Development of Checkpoint Inhibitors for GU Cancers

Panelists: Robert Dreicer, MD, Cleveland Clinic; Omid Hamid, MD, Angeles Clinic;Roy S. Herbst, MD, PhD, Yale; Mark A. Socinski, MD, UPMC; Louis
Published: Friday, Nov 14, 2014
For High-Definition, Click
Immunotherapies have been administered as treatments for patients with genitourinary cancers for many years, explains moderator Louis M. Weiner, MD. Treatment with interleukin 2 (IL-2) results in long-term survival in 5% to 10% of patients. However, despite impressive outcomes for these patients, the low number of responders hampered the widespread use of the drug.

If similar results to IL-2 could be broadened to 20% to 25% of patients it could warrant widespread use of the therapy, Robert Dreicer, MD, notes. Several treatments are approved for patients with renal cell carcinoma, making new drug development difficult, Dreicer notes. As a result, most new treatments get tested in the second- or third-line. However, the checkpoint inhibitors should be explored in the frontline setting, the panel agrees.

The optimal duration of treatment with an immune checkpoint inhibitor remains unclear. Interestingly, patients who respond and stop treatment will respond again when retreated, Dreicer notes. This could result in an arbitrary stopping point for treatment following a suitable response, with close monitoring plus retreatment or maintenance when needed, Dreicer believes.

One of the advantages of the PD-1 and PD-L1 inhibitors is the rapidity of response, notes Omid Hamid, MD. The kinetics of these checkpoint inhibitors is very different from anti-CTLA-4 therapies. In general, 80% to 90% of responses occur by the first scan for patients who respond to PD-1/PD-L1 inhibitors, Hamid notes.
Slider Left
Slider Right
For High-Definition, Click
Immunotherapies have been administered as treatments for patients with genitourinary cancers for many years, explains moderator Louis M. Weiner, MD. Treatment with interleukin 2 (IL-2) results in long-term survival in 5% to 10% of patients. However, despite impressive outcomes for these patients, the low number of responders hampered the widespread use of the drug.

If similar results to IL-2 could be broadened to 20% to 25% of patients it could warrant widespread use of the therapy, Robert Dreicer, MD, notes. Several treatments are approved for patients with renal cell carcinoma, making new drug development difficult, Dreicer notes. As a result, most new treatments get tested in the second- or third-line. However, the checkpoint inhibitors should be explored in the frontline setting, the panel agrees.

The optimal duration of treatment with an immune checkpoint inhibitor remains unclear. Interestingly, patients who respond and stop treatment will respond again when retreated, Dreicer notes. This could result in an arbitrary stopping point for treatment following a suitable response, with close monitoring plus retreatment or maintenance when needed, Dreicer believes.

One of the advantages of the PD-1 and PD-L1 inhibitors is the rapidity of response, notes Omid Hamid, MD. The kinetics of these checkpoint inhibitors is very different from anti-CTLA-4 therapies. In general, 80% to 90% of responses occur by the first scan for patients who respond to PD-1/PD-L1 inhibitors, Hamid notes.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x